Oral Glucose Tolerance Test for Parkinson's (NCT05998772)
Improve motor symptoms via glucose
- Trial ID
- NCT05998772
- Official Title
- Influence of Glucose on Metabolism and Clinical Symptoms of Patients With Parkinson's Disease
- Goal
- Improve motor symptoms via glucose
- Status
- RECRUITING
- Sponsor
- University Hospital Schleswig-Holstein
- Study Type
- OBSERVATIONAL
- Enrollment
- 50 participants
- Conditions
- Parkinson Disease, Nutritional and Metabolic Diseases, Sugar Intake
- Interventions
- Oral Glucose Tolerance Test, Placebo Oral Glucose Tolerance Test
Summary For Families
The goal is to see how a glucose challenge changes metabolism and short-term Parkinson's symptoms, and whether people who crave sweets react differently. Participants get an oral glucose tolerance test and a placebo version, so researchers can compare blood glucose and metabolic markers along with motor and nonmotor symptom changes after a sugary drink versus a non‑sugar control; participants pause their morning Parkinson meds to avoid confounding. The trial is looking for people aged 50 to 80 with Parkinson's at Hoehn and Yahr stage 1.5 to 3 who can give consent and can safely skip their morning antiparkinsonian meds. People with diabetes or prediabetes, pacemakers, or on medications that affect glucose metabolism are excluded.
Locations
- Department for Neurology, University of Kiel, Kiel, Germany
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Oral Glucose Tolerance Test. The goal is to see how a glucose challenge changes metabolism and short-term Parkinson's symptoms, and whether people who crave sweets react differently. Participants get an oral glucose tolerance test and a placebo version, so researchers can compare blood glucose and metabolic markers along with motor and nonmotor symptom changes after a sugary drink versus a non‑sugar control; participants pause their morning Parkinson meds to avoid confounding. The trial is looking for people aged 50 to 80 with Parkinson's at Hoehn and Yahr stage 1.5 to 3 who can give consent and can safely skip their morning antiparkinsonian meds. People with diabetes or prediabetes, pacemakers, or on medications that affect glucose metabolism are excluded.
- Who can participate?
- Participants must be between 50 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 3 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.